Overview
Miroculus, now part of Integra LifeSciences, represents the cutting edge of lab automation through its Miro Canvas platform. The system utilizes Digital Microfluidics (DMF) technology, which manipulates discrete droplets of fluids using electrical signals on a chip, eliminating the need for traditional robotic pipetting arms for internal processing. By 2026, the Miroculus architecture has become a staple in decentralized clinical genomics, providing a 'walk-away' solution for complex Next-Generation Sequencing (NGS) library preparation. The platform integrates machine learning algorithms to optimize protocol execution, ensuring high-fidelity reagent mixing and thermal cycling precision. Its technical architecture allows for the automation of protocols from Illumina, Oxford Nanopore, and Pacific Biosciences. Unlike traditional automation, Miroculus focuses on minimizing reagent dead volume and reducing human error through a closed-system design. The platform is positioned as a critical bridge between raw sample acquisition and high-throughput sequencing, offering a scalable solution for labs that require high reproducibility without the footprint of massive liquid handling workstations. Its software ecosystem allows for cloud-based monitoring and protocol sharing, standardizing genomic workflows across global research networks.